Comparison of AAIsafeR and DDD Modes in Non-selected Patients
Launched by SORIN GROUP CANADA · Oct 12, 2010
Trial Information
Current as of June 10, 2025
Completed
Keywords
ClinConnect Summary
In patients with sinus node dysfunction (SND), the use of AAI mode is rare. In paroxysmal high-degree or complete atrio-ventricular (AV) block, paroxysmal vagally-mediated bradycardia, single chamber atrial pacemakers are contraindicated although ventricular support is only rarely needed. As a result, these patients are usually exposed to an unnecessary high proportion of ventricular pacing due to the programming of the system to DDD mode for preventive safety reasons. This drains the pulse generator battery, and more importantly has long-term adverse effects on ventricular function in a su...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Inclusion criteria / Indications Any patient who fulfils one or more of the official guidelines to be implanted with a dual-chamber pacemaker (primo-implantation) may be included in the study.
- Exclusion Criteria:
- • Exclusion criteria / Contraindications
- The patients presenting with one or more of the following characteristics cannot be included:
- • Permanent complete AV block
- • Permanent atrial and/or ventricular arrhythmias
- • already implanted with a cardioverter-defibrillator (ICD)
- * Likely to have a cardiac surgery in the next six months, mainly for:
- • severe coronary artery disease
- • severe valvular disease
- • Refuses to sign an consent form after having received the appropriate information
- • Refuses to co-operate
- • Not able to understand the study objectives and protocol
- • Not available for scheduled follow-up
- • With a life expectancy less than one year
- • Already included into another clinical study competing with the objectives of the CAN-SAVE R study.
- • \<18 years old.
- • Contraindications Any patient to whom a contraindication from device labeling applies shall not be included in the study.
- • -
About Sorin Group Canada
Sorin Group Canada, a leading entity in the medical device industry, specializes in innovative solutions for the treatment of cardiovascular and surgical conditions. Committed to advancing healthcare, the organization focuses on developing cutting-edge technologies and therapies that enhance patient outcomes and streamline clinical practices. With a strong emphasis on research and development, Sorin Group Canada collaborates with healthcare professionals and institutions to conduct clinical trials that rigorously evaluate the safety and efficacy of its products. Through its dedication to quality and innovation, Sorin Group Canada aims to improve the lives of patients and support the advancement of medical science.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Kingston, Ontario, Canada
Edmonton, Alberta, Canada
Edmonton, Alberta, Canada
Newmarket, Ontario, Canada
Toronto, Ontario, Canada
Montreal, Quebec, Canada
St Jerome, Quebec, Canada
Ste Foy, Quebec, Canada
Trois Rivieres, Quebec, Canada
Saskatoon, Saskatchewan, Canada
Patients applied
Trial Officials
Bernard Thibault, MD, IntMed,Cardiologist
Principal Investigator
Institute de Cardilogie Montreal, Montreal Hear t Institute
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials